An evaluation of the benefits of taking hormone replacement therapy with other prescription drugs

Maturitas

Volumn 46, Issue 4, 2003, Pages 273-281

  Jacobs, Pamela A ^a   Hyland, Michael E ^a  

^a UNIVERSITY OF PLYMOUTH   (United Kingdom)

Author keywords

Compliance; Estrogen; Hormone supplement; Prophylactic; Quality of life

Indexed keywords

ESTROGEN; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EVALUATION; FEMALE; HEALTH STATUS; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; POPULATION RESEARCH; PRESCRIPTION; QUALITY OF LIFE; QUESTIONNAIRE;

EID: 0242475234     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(03)00198-1     Document Type: Article

References (29)

1. Quine L., Rubin R. Attitude, subjective norm and perceived behavioural control as predictors of women's intentions to take hormone replacement therapy. Br. J. Health Psychol. 2:1997;199-216.
2. Jacobs P.A., Hyland M.E., Ley A. Self-rated menopausal status and quality of life in women aged 40-63. Br. J. Health Psychol. 5:2000;395-411.
3. Buist D.S.M., LaCroix A.Z., Newton K.M., Keenan N.L. Are long term hormone replacement therapy users different from short-term and never users? Am. J. Epidemiol. 149:1999;275-281.
4. Luoto R., Mannisto S., Vartianen E. Hormone replacement therapy and body size: how much does lifestyle explain? Am. J. Obstet. Gynaecol. 178:1998;66-73.
5. Lancaster T., Surman G., Lawrence M., Mant D., Vessey M., Thorogood M., et al. Characteristics of users and nonusers in a British general-practice cohort unidentified through computerised prescribing records. J. Epidemiol. Commun. Health. 49:1995;389-394.
6. Stevenson J.C. Mechanisms whereby estrogens influence arterial health. Eur. J. Gynaecol. Reprod. Biol. 65:1996;39-42.
7. Griewing B., Romer T., Spitzer C., Ludemann J., Gunther A., Kessler C. Hormone replacement therapy in post menopausal women: coriti intima-media thickness and 3-D volumetric plaque quantification. Maturitas. 32:1999;33-40.
8. Harlap S. The benefits and risks of hormone replacement therapy: an epidemiological overview. Am. J. Obstet. Gynaecol. 166:1992;1986-1992.
9. Barrett-Connor E. Risks and benefits of replacement therapy. Ann. Rev. Med. 734:1994;271-284.
10. Hammond C.B. Menopause and hormone replacement therapy: an overview. Obstet. Gynaecol. 87:1996;2S-15S.
11. Groeneveld F.P.M.J., Bareman F.P., Barentsen R., Dokter H.J. Duration of hormonal replacement therapy in general practice: a follow-up study. Maturitas. 31:1998;125-131.
12. Kadri A.Z. Hormone replacement therapy - a survey of peri-menopausal women in a community setting. Br. J. Gen. Pract. 41:1991;109-112.
13. Hee P. Compliance to estrogen treatment one to three years after hysterectomy and bilateral salping oopherectomy. The cohort's lifestyle and knowledge of ERT. Acta Obstet. Gynecol. Scand. 6:1999;534-539.
14. Schairer C., Byrne C., Keyl P.M. Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer (United States). Cancer Causes Control. 5:1994;491-500.
15. Zweifel J.E., O'Brien W.H. A meta-analysis of the effect of hormone replacement therapy upon depressed mood. Psychoneuroendocinology. 22:1997;189-212.
16. Carlson L.E., Sherwin B.B. Steroid hormones, memory and mood in a healthy elderly population. Psychoneuroendocrinology. 23:1998;583-603.
17. Reiger D.A., Boyd J.H., Burke J.D., Rae D.S., Myers J.K., Kramer M., et al. One month prevalence of mental disorders in the United States: based on five epidemiological catchment area sites. Arch. Gen. Psychiat. 45:1988;977-986.
18. Weissman M.M., Olfson M. Depression in women: implications for health care research. Science. 269:1995;799-801.
19. Cluberston F.M. Depression and gender: an international review. Am. Psychol. 52:1997;25-31.
20. Studd J., Watson N.R., Montgomery J. Depression and the menopause. Br. Med. J. 300:1990;1653.
21. Halbreich U. Role of estrogens in postmenopausal depression. Neurology. 45:(5 Suppl 7):1997;S16-S19.
22. Genazzani A.R. Hormonal influence on the central nervous system. Maturitas. 43:(Suppl):2002;s11-s17.
23. Nagata H., Nozaki M., Egami R., Nakano H. Estrogen replacement therapy plus selective serotonin re-uptake inhibitor in the treatment of depression during the climacteric. Menopause. 8:2001;476.
24. Robinson G.E. Psychotic and mood disorders associated with the peri-menopausal period: epidemiology, aetiology and management. CNS Drugs. 15:(3):2001;175-184.
25. Gunzelmann T. The quality of life of the elderly patient with chronic illness. Zeitschrift fur Klinische psychologie psychiatrie und psychotherapie 1999; 47:123-40.
26. Fava G.A. Depression associated with medical illness - treatment considerations. CNS Drugs. 5:1996;175-189.
27. Bebbington P.E., Dunn G., Jenkins R., Lewis G., Brugha T., Farell M., et al. The influence of age and sex on the prevalence of depressive conditions: report for the national survey of psychiatric morbidity. Psychol. Med. 28:1998;9-19.
28. Dennerstein L., Smith A.M.A., Morse C.A. Psychological well-being mid-life and the menopause. Maturitas. 20:1994;1-11.
29. Maartens L.W., Leusink G.L., Knotnerus J.A., Pop V.J. Hormonal substitution during menopause: what are we treating? Maturitas. 34:2000;113-118.